Install
Clinical Trials (Phases I–IV)
Design, endpoints, enrollment, interim reads, and post‑market surveillance.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Clinical Trials (Phases I–IV)
Can Acetylcholine Receptor Antibody Profiling Predict FcRn Therapy Outcomes in MG?
2+ day, 4+ hour ago (296+ words) Dr. Iorio: My name is Raffaele Iorio. I’m an associate professor of neurology at the Universita Cattolica del Sacro Cuore in Rome, Italy. I am also a staff neurologist at the Fondazione Policlinico Gemelli in Rome, Italy. Rare Diseases Today:…...
ARWR: Strong efficacy, safety, and launch readiness position plozasiran for high-impact SHTG entry
2+ day, 12+ hour ago (83+ words) tradingview.com Recent clinical data for plozasiran in SHTG show strong efficacy and a differentiated safety profile, with positive physician feedback and a focus on high-risk patient segments. Launch preparations are advanced, pricing has been well received by payers, and…...
Biovie seeks FDA meeting to plan Phase 3 trial for Parkinson's drug
2+ day, 16+ hour ago (532+ words) Planned study of bezisterim would enroll 175 adults with early-stage disease Written by Andrea Lobo | Sept. 10, 2026 Bezisterim, an experimental oral small molecule that Biovie is developing for people with early-stage Parkinson’s disease, is moving toward Phase 3 clinical testing, with the company…...
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
2+ day, 17+ hour ago (205+ words) Emerge Phase 3 study podium poster to be featured in “Latest Discoveries & Emerging Trends in MDD” session New epidemiological research on risks associated with anxiety and depression plus five posters across clinical program NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium…...
IFRX: INF904 advances in ANCA vasculitis with phase II trials planned and strong regulatory engagement
3+ day, 8+ hour ago (78+ words) TradingView IFRX: INF904 advances in ANCA vasculitis with phase II trials planned and strong regulatory engagement A strategic pivot prioritizes ANCA vasculitis with INF904, designed for better safety and efficacy, and vilobelimab as a bridging option amid competitor withdrawals. Regulatory engagement is…...
IMUX: Pivotal Phase 3 data for vidofludimus calcium in relapsing MS expected by end of 2026
3+ day, 12+ hour ago (84+ words) TradingView IMUX: Pivotal Phase 3 data for vidofludimus calcium in relapsing MS expected by end of 2026 Vidofludimus calcium is advancing through pivotal Phase 3 trials in relapsing MS, with top-line data expected by end of 2026 and a U.S. NDA submission targeted for mid-2027. The…...
Crossbow Therapeutics Doses First Patient In Phase 1 Trial Of CBX-663 For Hematologic And Solid Tumors
3+ day, 13+ hour ago (333+ words) Crossbow Therapeutics has dosed the first patient in the TelOscope-001 Phase 1 clinical trial of CBX-663, a first-in-class T-cell engager being developed for multiple hematologic and solid tumors. CBX-663 is the second candidate developed through Crossbow’s T-Bolt platform, a portfolio of…...
Leyden Labs advances RIG-101 after Phase I shows safety and on-target immune activation
3+ day, 16+ hour ago (543+ words) AllSci Phase I data from Netherlands-based Leyden Laboratories B.V.'s intranasal innate immune modulator RIG-101 showed acceptable safety and on-target pharmacodynamic activity in both healthy volunteers and asthma patients, clearing the path to a Phase I/II rhinovirus challenge study, the…...
BridgeBio Pharma Reports Favorable Exploratory PROPEL 3 Data for Oral Infigratinib in Achondroplasia, Including Sleep Apnea and Ear Infection Trends | BBIO Stock News
3+ day, 21+ hour ago (437+ words) 50% off your first year of any Quiver subscription Oral infigratinib shows promise in improving sleep apnea, ear infection rates, and growth in children with achondroplasia. The PROPEL 3 study showed oral infigratinib improved growth, reduced sleep apnea, and lowered ear infection…...
PHVS: Deucrictibant XR reduced HAE attacks by 83% and was well-tolerated, with strong quality of life gains
4+ day, 14+ hour ago (84+ words) TradingView PHVS: Deucrictibant XR reduced HAE attacks by 83% and was well-tolerated, with strong quality of life gains The phase III CHAPTER-3 study showed deucrictibant XR achieved an 83% reduction in HAE attack rates versus placebo, with nearly half of treated patients…...